Integral Health Asset Management LLC Acquires 50,000 Shares of Glaukos Corporation $GKOS

Integral Health Asset Management LLC grew its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 100.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 100,000 shares of the medical instruments supplier’s stock after acquiring an additional 50,000 shares during the period. Integral Health Asset Management LLC owned about 0.17% of Glaukos worth $8,155,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. UMB Bank n.a. increased its holdings in Glaukos by 102.6% in the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 158 shares during the period. REAP Financial Group LLC acquired a new position in Glaukos during the 3rd quarter worth about $40,000. SBI Securities Co. Ltd. lifted its holdings in Glaukos by 42.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock worth $98,000 after buying an additional 362 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 136 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Glaukos by 4,970.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,724 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 1,690 shares during the period. Institutional investors own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on GKOS shares. Piper Sandler restated an “overweight” rating and set a $165.00 price objective on shares of Glaukos in a research report on Wednesday, January 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Stephens raised their price target on shares of Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, January 2nd. Finally, Wells Fargo & Company upped their price objective on shares of Glaukos from $122.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.69.

Glaukos Stock Down 0.9%

Shares of Glaukos stock opened at $96.89 on Friday. The stock’s 50-day moving average is $114.63 and its 200 day moving average is $101.20. Glaukos Corporation has a one year low of $73.16 and a one year high of $130.23. The firm has a market cap of $5.63 billion, a price-to-earnings ratio of -29.72 and a beta of 0.70. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06.

Glaukos (NYSE:GKOS) last issued its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The business had revenue of $143.12 million during the quarter, compared to the consensus estimate of $132.16 million. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. The company’s revenue for the quarter was up 35.6% compared to the same quarter last year. Equities research analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Insider Activity at Glaukos

In other news, Director Marc Stapley sold 15,000 shares of Glaukos stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total value of $1,915,650.00. Following the completion of the sale, the director owned 37,449 shares in the company, valued at $4,782,611.79. The trade was a 28.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Joseph E. Gilliam sold 10,498 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total transaction of $1,340,384.64. Following the transaction, the chief operating officer owned 92,366 shares in the company, valued at $11,793,290.88. The trade was a 10.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 320,000 shares of company stock worth $37,202,909. 5.80% of the stock is owned by insiders.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.